MaxCyte Toekomstige groei

Future criteriumcontroles 2/6

MaxCyte zal naar verwachting groeien in winst en omzet met respectievelijk 9% en 20.9% per jaar. De winst per aandeel zal naar verwachting groeien met 9.8% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -16.3% zijn.

Belangrijke informatie

9.0%

Groei van de winst

9.8%

Groei van de winst per aandeel

Life Sciences winstgroei	19.8%
Inkomstengroei	20.9%
Toekomstig rendement op eigen vermogen	-16.3%
Dekking van analisten	Good
Laatst bijgewerkt	30 Oct 2024

Recente toekomstige groei-updates

MaxCyte, Inc. (LON:MXCT) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Aug 09

Analysts Are Upgrading MaxCyte, Inc. (LON:MXCT) After Its Latest Results

May 10

Recent updates

MaxCyte, Inc. (LON:MXCT) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Aug 09

Investors Appear Satisfied With MaxCyte, Inc.'s (LON:MXCT) Prospects As Shares Rocket 27%

May 30

Analysts Are Upgrading MaxCyte, Inc. (LON:MXCT) After Its Latest Results

May 10

Downgrade: Here's How Analysts See MaxCyte, Inc. (LON:MXCT) Performing In The Near Term

Mar 14

MaxCyte, Inc. (LON:MXCT) Analysts Just Slashed This Year's Revenue Estimates By 11%

May 15

Investors Don't See Light At End Of MaxCyte, Inc.'s (LON:MXCT) Tunnel And Push Stock Down 28%

May 14

We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth

Apr 27

Companies Like MaxCyte (LON:MXCT) Are In A Position To Invest In Growth

Nov 20

Here's Why We're Not Too Worried About MaxCyte's (LON:MXCT) Cash Burn Situation

Mar 02

We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth

Nov 17

We're Not Worried About MaxCyte's (LON:MXCT) Cash Burn

Jul 25

MaxCyte (LON:MXCT) Shareholders Have Enjoyed A Whopping 545% Share Price Gain

Feb 22

Winst- en omzetgroeiprognoses

AIM:MXCT - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	62	-35	-47	N/A	5
12/31/2025	46	-42	-53	N/A	8
12/31/2024	37	-45	-54	N/A	8
6/30/2024	45	-35	-25	-23	N/A
3/31/2024	44	-37	-31	-28	N/A
12/31/2023	41	-38	-25	-22	N/A
9/30/2023	38	-37	-34	-29	N/A
6/30/2023	41	-33	-34	-26	N/A
3/31/2023	41	-30	-29	-15	N/A
12/31/2022	44	-24	-33	-15	N/A
9/30/2022	42	-24	-27	-10	N/A
6/30/2022	41	-20	-20	-4	N/A
3/31/2022	39	-16	-19	-10	N/A
12/31/2021	34	-19	-15	-11	N/A
9/30/2021	32	-17	-15	-12	N/A
6/30/2021	29	-17	-14	-12	N/A
3/31/2021	27	-16	-10	-8	N/A
12/31/2020	26	-12	-11	-9	N/A
9/30/2020	24	-11	-10	-8	N/A
6/30/2020	24	-9	-10	-8	N/A
3/31/2020	23	-11	-13	-11	N/A
12/31/2019	22	-13	-10	-9	N/A
9/30/2019	20	-13	-11	-10	N/A
6/30/2019	18	-14	-11	-10	N/A
3/31/2019	17	-11	-11	-10	N/A
12/31/2018	17	-9	-11	-10	N/A
9/30/2018	16	-10	-11	-11	N/A
6/30/2018	15	-10	-12	-11	N/A
3/31/2018	14	-10	N/A	-10	N/A
12/31/2017	14	-10	N/A	-10	N/A
9/30/2017	13	-8	N/A	-8	N/A
6/30/2017	13	-6	N/A	-6	N/A
3/31/2017	13	-5	N/A	-4	N/A
12/31/2016	12	-4	N/A	-2	N/A
9/30/2016	11	-4	N/A	-2	N/A
6/30/2016	11	-3	N/A	-2	N/A
3/31/2016	10	-3	N/A	-1	N/A
12/31/2015	9	-4	N/A	0	N/A
9/30/2015	9	-4	N/A	0	N/A
6/30/2015	8	-4	N/A	0	N/A
3/31/2015	8	-4	N/A	-1	N/A
12/31/2014	7	-4	N/A	-2	N/A
12/31/2013	7	-3	N/A	-1	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat MXCT de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat MXCT de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat MXCT de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van MXCT ( 20.9% per jaar) zal naar verwachting sneller groeien dan de markt UK ( 3.6% per jaar).

Hoge groei-inkomsten: De omzet van MXCT ( 20.9% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Er wordt voorspeld dat MXCT binnen 3 jaar verliesgevend zal zijn.

MaxCyte Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

MaxCyte, Inc. (LON:MXCT) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

MaxCyte, Inc. Reaffirms Revenue Guidance for the Full Year 2024

Analysts Are Upgrading MaxCyte, Inc. (LON:MXCT) After Its Latest Results

Maxcyte, Inc. Affirms Revenue Guidance for the Full Year 2024

Consensus revenue estimates fall by 13%

MaxCyte, Inc. Reiterates Earnings Guidance for the Year 2024

Recent updates

MaxCyte, Inc. Announces Appointment of Cynthia Collins as Non-Executive Director

MaxCyte, Inc. to Report Q3, 2024 Results on Nov 06, 2024

MaxCyte, Inc. Appoints Ali Soleymannezhad as Chief Commercial Officer

Independent Non-Executive Director exercised options and sold UK£133k worth of stock

Independent Non-Executive Director notifies of intention to sell stock

MaxCyte, Inc. (LON:MXCT) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

MaxCyte, Inc. Reaffirms Revenue Guidance for the Full Year 2024

MaxCyte, Inc. to Report Q2, 2024 Results on Aug 06, 2024

MaxCyte, Inc.(NasdaqGS:MXCT) dropped from Russell 2500 Growth Index

Insider notifies of intention to sell stock

President recently bought UK£384k worth of stock

Investors Appear Satisfied With MaxCyte, Inc.'s (LON:MXCT) Prospects As Shares Rocket 27%

Analysts Are Upgrading MaxCyte, Inc. (LON:MXCT) After Its Latest Results

New major risk - Revenue and earnings growth

Maxcyte, Inc. Affirms Revenue Guidance for the Full Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

MaxCyte, Inc., Annual General Meeting, Jun 11, 2024

MaxCyte, Inc. to Report Q1, 2024 Results on May 07, 2024

Consensus revenue estimates fall by 13%

MaxCyte, Inc. Reiterates Earnings Guidance for the Year 2024

Downgrade: Here's How Analysts See MaxCyte, Inc. (LON:MXCT) Performing In The Near Term

Full year 2023 earnings: EPS and revenues exceed analyst expectations

MaxCyte, Inc. Provides Revenue Guidance for the Fiscal Year 2023 and 2024

Here's Why We're Not Too Worried About MaxCyte's (LON:MXCT) Cash Burn Situation

MaxCyte, Inc. to Report Fiscal Year 2023 Results on Mar 12, 2024

MaxCyte, Inc. Announces Departure of Cenk Sumen as Chief Scientific Officer

MaxCyte, Inc. Provides Preliminary Financial Guidance for the Fourth Quarter and Full Year Ended December 31, 2023

MaxCyte, Inc. Provides Revenue Guidance Update for 2023

Founder exercised options and sold UK£100k worth of stock

Independent Non-Executive Director notifies of intention to sell stock

New major risk - Revenue and earnings growth

MaxCyte, Inc. Provides Revenue Guidance for the Year 2023

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

New minor risk - Share price stability

MaxCyte, Inc. Provides Revenue Guidance for the Third Quarter and Full Year of 2023

Analysts Have Just Cut Their MaxCyte, Inc. (LON:MXCT) Revenue Estimates By 22%

Consensus revenue estimates fall by 22%

MaxCyte, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Maxcyte, Inc. Appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing

New major risk - Revenue and earnings growth

Here's Why We're Not Too Worried About MaxCyte's (LON:MXCT) Cash Burn Situation

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

MaxCyte, Inc. Provides Revenue Guidance for the Year 2023

MaxCyte, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Founder notifies of intention to sell stock

Independent Non-Executive Director notifies of intention to sell stock

Founder exercised options and sold UK£173k worth of stock

Consensus revenue estimates fall by 11%

MaxCyte, Inc. (LON:MXCT) Analysts Just Slashed This Year's Revenue Estimates By 11%

Investors Don't See Light At End Of MaxCyte, Inc.'s (LON:MXCT) Tunnel And Push Stock Down 28%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

MaxCyte, Inc. Provides Revenue Guidance for the Year 2023

We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth

High number of new directors

Key Executive recently bought UK£280k worth of stock

Full year 2022 earnings released: US$0.23 loss per share (vs US$0.21 loss in FY 2021)

Founder exercised options and sold UK£139k worth of stock

MaxCyte, Inc. to Report Q4, 2022 Results on Mar 15, 2023

Founder exercised options and sold UK£127k worth of stock

Insider exercised options and sold UK£113k worth of stock

MaxCyte, Inc. Appoints Patrick J. Balthrop, Sr. as Class II Director and Member of Nominating Committee and Corporate Governance Committee

Companies Like MaxCyte (LON:MXCT) Are In A Position To Invest In Growth

Consensus forecasts updated

MaxCyte, Inc. Provides Revenue Guidance for 2022

Insider exercised options and sold UK£154k worth of stock

Insider exercised options and sold UK£147k worth of stock

MaxCyte, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Consensus forecasts updated